New single-cell protocols available for full-length, whole transcriptome sequencing using microfluidics technology SOUTH SAN FRANCISCO, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies, today announced two new total RNA
Visiopharm Phenomap software presented at the Fluidigm Imaging Mass Cytometry User Group Meeting, expanding the suite of Hyperion Imaging System data analysis tools for translational and clinical research SOUTH SAN FRANCISCO, Calif. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation
Providing a best-in-class solution for immuno-oncology research, from RNA extraction to comprehensive data analysis, to advance therapeutic development SOUTH SAN FRANCISCO, Calif. , Sept. 07, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and GenomOncology today announced an expanded
SOUTH SAN FRANCISCO, Calif. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s management team will participate in three upcoming investor conferences in New York : Vikram Jog, Chief
Leading translational and clinical researchers to share new insights and best practices using Imaging Mass Cytometry SOUTH SAN FRANCISCO, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies, today announced it will hold its 2nd
SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of July 31, 2018 , under Fluidigm's
Total revenue increases 11 percent to $26.4 million Mass cytometry revenue growth of 32 percent Total consumables revenue growth of 19 percent SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced financial results for the second quarter
Providing more affordable full-length single-cell mRNA sequencing with industry-leading coverage and sensitivity for in-depth cellular characterization SOUTH SAN FRANCISCO, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies,
Pairing epigenetic profiling with T cell receptor sequencing at single-cell resolution to advance cancer, immunology and stem cell research SOUTH SAN FRANCISCO, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies, today
SOUTH SAN FRANCISCO, Calif. , July 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative life science company that develops, manufactures and markets multiparameter mass cytometry and proprietary microfluidics systems used in research and applied markets, announced today
